VX-407

Small molecule

Earlyevidence

Evidence outlook

Mid-stage studies underway, no completed readout

Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (1)
Autosomal Dominant Polycystic Kidney Disease
Phase 1 (5)
Autosomal Dominant Polycystic Kidney Disease
NCT07792408 · Vertex Pharmaceuticals Incorporated
2026-09-01 – 2027-03-20 · Autosomal Dominant Polycystic Kidney Disease (ADPKD)
What this study did
NCT07868926 · Vertex Pharmaceuticals Incorporated
2026-10-16 – 2026-12-15 · Autosomal Dominant Polycystic Kidney Disease (ADPKD)
What this study did
NCT07074327 · Vertex Pharmaceuticals Incorporated
2025-07-11 – 2026-02-27 · Autosomal Dominant Polycystic Kidney Disease (ADPKD)
What this study did
NCT07022119 · Vertex Pharmaceuticals Incorporated
2025-06-12 – 2026-02-24 · Autosomal Dominant Polycystic Kidney Disease (ADPKD)
What this study did

Competitive landscape

This drug's own stage for Autosomal Dominant Polycystic Kidney Disease: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
VX-407: this drugPhase 2Small moleculePolycystin-1 (PKD1 variants)not yet gradedNo reviewed efficacy summary in this indication
Tolvaptan (Jynarque)ApprovedSmall moleculeVasopressin V2 receptorPartial signal
NCT02160145: Annualized change in eGFR (REPRISE trial): -2.34 mL/min/1.73m2/year tolvaptan vs -3.61 mL/min/1.73m2/year placebo; difference 1.27 mL/min/1.73m2/year (95% CI 0.86-1.68), 35% reduction in decline, P<0.001
NCT00428948: Total kidney volume growth over 36 months: tolvaptan 2.78% per year vs placebo 5.61% per year; difference -2.71 percentage points per year (95% CI -3.27 to -2.15), p<0.0001 (n=819 and 458 analysed) (CT.gov posted results).
AZD1613Phase 1Monoclonal antibodyPAPP-Anot yet gradedNo reviewed efficacy summary in this indication
GSK4771261Phase 1Monoclonal antibody—not yet gradedNo reviewed efficacy summary in this indication
Farabursen
—(overall)
RNA / oligonucleotidemiR-17not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow VX-407 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 1Autosomal Dominant Polycystic Kidney DiseaseRecruiting
Est. primary completion 2026-12-15 · NCT07868926 · CT.gov ↗
What to watch
2027 (2)
March 2027 (1)
Phase 1Autosomal Dominant Polycystic Kidney DiseaseRecruiting
Est. primary completion 2027-03-11 · NCT07792408 · CT.gov ↗
What to watch
July 2027 (1)
Phase 2Autosomal Dominant Polycystic Kidney DiseaseActive not recruiting
Est. primary completion 2027-07-22 · NCT07161037 · CT.gov ↗
What to watch

See the full readout calendar ↗